Summary
The vascular endothelial growth factor (VEGF) has been shown to be strictly related to vascular permeability and endothelial cell growth under physiological and pathological conditions. In tumour development and progression, VEGF plays a pivotal role in the development of the tumoral vascular network, and useful information in the progression of human cancer can be obtained by analysing the vascular endothelial growth factor expression of the tumours. In this study, we investigated the vascular endothelial growth factor transcript expression in non-small-cell lung carcinomas to evaluate the significance of this factor in a group of cancers in which the vascular pattern has been shown to significantly affect progression. Surgical samples of 42 patients with NSCLC were studied using reverse transcription polymerase chain reaction (PCR) analysis and in situ hybridization. Thirty-three out of 42 cases (78.6%) showed VEGF transcript expression predominantly as transcripts for the secretory forms of VEGF (isoforms 121 and 165). In situ hybridization, performed on 24 out of 42 samples, showed that the VEGF transcript expression was in several cases present in the cytoplasm both of neoplastic and normal cells, even if the VEGF mRNA was less expressed in the corresponding non-tumoral part. The VEGF 121 expression was associated with hilar and/or mediastinal nodal involvement (P = 0.02), and, taken together, the VEGF isoforms were shown to significantly influence overall (P = 0.02) and disease-free survival (P = 0.03). As a regulator of tumour angiogenesis, VEGF may represent a useful indicator of progression and poor prognosis in non-small-cell lung carcinomas.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abu-Jawdeh, G. M., Faix, J. D., Niloff, J., Tognazzi, K., Manseau, E., Dvorak, H. F. & Brown, L. F. (1996). Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74: 1105–1115.
American Joint Committee on Cancer (1992). Manual for a Staging of Cancer. 4th edn. Beahrs OH, Henson DE, Hutter RU, Myers MH (eds), pp. 115–122, JP Lipincott: Philadelphia PA
Angeletti, C. A., Lucchi, M., Fontanini, G., Mussi, A., Chella, A., Ribechini, A., Vignati, S. & Bevilacqua, G. (1996). Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA–N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer 78: 409–415.
Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F. & Senger, D. R. (1993). Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143: 1255–1262.
Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Guidi, A. J., Dvorak, H. F., Senger, D. R., Connoly, J. L. & Schnitt, S. J. (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26: 86–91.
Ferrara, N. (1995). The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treatment 36: 127–137.
Fontanini, G., Bigini, D., Vignati, S., Basolo, F., Mussi, A., Lucchi, M., Chinè, S., Angeletti, C. A., Harris, A. L. & Bevilacqua, G. (1995). Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 177: 57–63.
Fontanini, G., Vignati, S., Boldrini, L., Chinè, S., Silvestri, V., Lucchi, M., Mussi, A., Angeletti, C. A. & Bevilacqua, G. (1997). Vascular endothelial growth factor (VEGF) is associated with neovascularization and influences progression of non-small cell lung carcinoma (NSCLC). Clin Cancer Res 3: 861–865.
Harpole, D. H., Richards, W. G., Herndon, J. E. & Sugarbaker, D. J. (1996). Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61: 1470–1476.
Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., LI, B. & Leung, D. W. (1991). The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806–1814.
Inoue, K., Ozeki, Y., Suganuma, T., Sugiura, Y. & Tanaka, S. (1997). Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 79: 206–213.
Macchiarini, P., Fontanini, G., Hardin, J. M., Squartini, F. & Angeletti, C. A. (1992). Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340: 45–46.
Maeda, K., Chung, Y., Ogawa, Y., Takatsuka, S., Kang, S. M., Ogawa, M., Sawada, T. & Sow, M. (1996). Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858–863.
Martiny-Baron, G. & Marmé, D. (1995). VEGF- mediated tumour angiogenesis: a new target for cancer therapy. Curr Opinion Biotechnol 6: 675–680.
Mattern, J., Koomagi, R. & Volm, M. (1995). Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Oncol 6: 1059–1062.
Mattern, J., Koomagi, R. & Volm, M. (1996). Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73: 931–934.
Ohta, Y., Endo, Y., Tanaka, M., Shimizu, J., Oda, M., Hayashi, Y., Watanabe, Y. & Sasaki, T. (1996). Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 2: 1411–1416.
Shibuya, M. (1995). Role of VEGF-FLT receptor system in normal and tumor angiogenesis. Adv Cancer Res 67: 281–316.
Suzuki, K., Hayashi, N., Miyamoto, Y., Yamamoto, M., Ohkawa, K., Ito, Y., Sasaki, Y., Yamaguchi, Y., Nakase, H., Noda, K., Enomoto, N., Arai, K., Yamada, Y., Yoshihara, H., Tujimura, T., Kawano, K., Yoshikawa, K. & Kamada, T. (1996). Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56: 3004–3009.
Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R. & Ellis, L. M. (1995). Expression of vascular endothelial growth factor and its receptors, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964–3968.
Takahashi, Y., Cleary, K. R., Mai, M., Kitadai, Y., Bucana, C. D. & Ellis, L. M. (1996). Significance of vessel count and vascular endothelial growth factor and its receptors (KDR) in intestinal type gastric cancer. Clin Cancer Res 2: 1679–1684.
Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C. & Abraham, J. A. (1991). The human gene for vascular endothelial growth factor. J Biol Chem 266: 11947–11954.
Toi, M., Kondo, S., Suzuki, H., Yamamoto, Y., Inada, K., Imazawa, T., Taniguchi, T. & Tominaga, T. (1996). Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77: 1101–1106.
Volm, M., Koomagi, R. & Mattern, J. (1996a). Vascular endothelial growth factor and basic fibroblast growth factor in primary lung carcinomas and the incidence of metastasis. Int J Oncol 9: 711–714.
Volm, M., Koomagi, R. & Mattern, J. (1996b). Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res 16: 213–218.
Wizigmann-Voos, S., Breier, G., Risau, W. & Plate, K. H. (1995). Up-regulation of vascular endothelial growth factor and its receptors in von Hippel–Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55: 1358–1364.
World Health Organization (1982). The World Health Organization. Histological typing of lung tumours. Am J Clin Pathol 77: 123–136.
Yoshiji, H., Gomez, D. E., Shibuya, M. & Thorgeirsson, U. P. (1996). Expression of vascular endothelial growth factor, its receptors, and other angiogenic factors in human breast cancer. Cancer Res 56: 2013–2016.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Fontanini, G., Boldrini, L., Chinè, S. et al. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 79, 363–369 (1999). https://doi.org/10.1038/sj.bjc.6690058
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690058
Keywords
This article is cited by
-
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study
British Journal of Cancer (2021)
-
Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy
Strahlentherapie und Onkologie (2014)
-
Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)
Targeted Oncology (2013)
-
Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India)
Tumor Biology (2012)
-
Synthesis and in vivo anticancer and antiangiogenic effects of novel thioxothiazolidin-4-one derivatives against transplantable mouse tumor
Medicinal Chemistry Research (2010)